Skip to main navigation
Investor Relations
Who We Are
Management
Board of Directors
Our Focus
Dismutase Mimetics
Reducing Oral Mucositis
Aiming to Increase Efficacy of Radiation Therapy
Our Pipeline
Avasopasem (GC4419)
Rucosopasem (GC4711)
Clinical Trials
Key Publications
Investors
IR Home
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Shareholder Services
Contact Us
Contact IR
Investor FAQs
Email Alerts
Contact IR
Name
Email
Subject
Comments
Leave this field blank
